Clinical Trial

Neural Circuit Effects of Ketamine in Depression

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-09; most recent amendment 2025-06-30.
Trial Details
NCT Number NCT06213324
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: National Institute of Mental Health (NIMH)
Conditions Major Depressive Disorder
Enrollment 120 participants
Start Date 2024-01-31
Primary Completion 2028-03-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-03